FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer

BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS). METHODS: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertolini, F, Malavasi, N, Scarabelli, L, Fiocchi, F, Bagni, B, Giovane, C Del, Colucci, G, Gerunda, G E, Depenni, R, Zironi, S, Fontana, A, Pettorelli, E, Luppi, G, Conte, P F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068493/
https://www.ncbi.nlm.nih.gov/pubmed/21386839
http://dx.doi.org/10.1038/bjc.2011.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068493/
https://www.ncbi.nlm.nih.gov/pubmed/21386839
http://dx.doi.org/10.1038/bjc.2011.43

Ejemplares similares